EA200401097A1 - MEDICAL FORM WITH ADJUSTABLE LIBERATION OF THE ACTIVE INGREDIENT - Google Patents

MEDICAL FORM WITH ADJUSTABLE LIBERATION OF THE ACTIVE INGREDIENT

Info

Publication number
EA200401097A1
EA200401097A1 EA200401097A EA200401097A EA200401097A1 EA 200401097 A1 EA200401097 A1 EA 200401097A1 EA 200401097 A EA200401097 A EA 200401097A EA 200401097 A EA200401097 A EA 200401097A EA 200401097 A1 EA200401097 A1 EA 200401097A1
Authority
EA
Eurasian Patent Office
Prior art keywords
active ingredient
dosage form
pharmaceutical dosage
release profile
liberation
Prior art date
Application number
EA200401097A
Other languages
Russian (ru)
Other versions
EA005866B1 (en
Inventor
Е. Ицхак Лернер
Веред Розенбергер
Офер Аква
Моше Флашнер-Барак
Original Assignee
Тева Фармасьютикал Индастриес Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриес Лтд. filed Critical Тева Фармасьютикал Индастриес Лтд.
Publication of EA200401097A1 publication Critical patent/EA200401097A1/en
Publication of EA005866B1 publication Critical patent/EA005866B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B30—PRESSES
    • B30B—PRESSES IN GENERAL
    • B30B11/00—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses
    • B30B11/34—Presses specially adapted for forming shaped articles from material in particulate or plastic state, e.g. briquetting presses, tabletting presses for coating articles, e.g. tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Mechanical Engineering (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Предлагается фармацевтическая лекарственная форма с профилем высвобождения активного ингредиента нулевого порядка для перорального приема, включающая сердцевинную таблетку, заключенную в кольцеобразную оболочку из порошкообразного или гранулированного материала. Предпочтительный вариант осуществления фармацевтической лекарственной формы с профилем высвобождения активного ингредиента нулевого порядка по предлагаемому изобретению представляет собой твердую фармацевтическую лекарственную форму, у которой ограничен контакт ее активного ингредиента с выстилающей слизистой оболочкой желудочно-кишечного тракта, что особенно важно при приеме лекарственных веществ, обладающих ульцерогенным действием. В настоящей заявке предлагается также способ получения фармацевтической лекарственной формы с профилем высвобождения активного ингредиента нулевого порядка.Международная заявка была опубликована вместе с отчетом о международном поиске.A pharmaceutical dosage form with a zero-order active ingredient release profile for oral administration is proposed, comprising a core tablet enclosed in a ring-shaped shell of a powdered or granular material. The preferred implementation of the pharmaceutical dosage form with the release profile of the active ingredient of zero order of the present invention is a solid pharmaceutical dosage form, which limits the contact of its active ingredient with the lining mucosa of the gastrointestinal tract, which is especially important when taking medicinal substances with ulcerogenic effects . This application also proposes a method for producing a pharmaceutical dosage form with a zero order active ingredient release profile. The international application was published along with an international search report.

EA200401097A 2002-03-04 2003-03-03 Active ingredient controlled release dosage form EA005866B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36182102P 2002-03-04 2002-03-04
US29161902A 2002-11-12 2002-11-12
PCT/US2003/006591 WO2003075893A1 (en) 2002-03-04 2003-03-03 Controlled release dosage forms

Publications (2)

Publication Number Publication Date
EA200401097A1 true EA200401097A1 (en) 2005-04-28
EA005866B1 EA005866B1 (en) 2005-06-30

Family

ID=27807664

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200401097A EA005866B1 (en) 2002-03-04 2003-03-03 Active ingredient controlled release dosage form

Country Status (13)

Country Link
EP (1) EP1492508A4 (en)
JP (1) JP2005524670A (en)
KR (1) KR20100049695A (en)
CN (1) CN1649569B (en)
AU (2) AU2003217909C1 (en)
BR (1) BR0308305A (en)
CA (1) CA2477701A1 (en)
EA (1) EA005866B1 (en)
IL (1) IL163887A0 (en)
MX (1) MXPA04008536A (en)
NO (1) NO20044188L (en)
NZ (1) NZ535083A (en)
WO (1) WO2003075893A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203296D0 (en) 2002-02-12 2002-03-27 Glaxo Group Ltd Novel composition
WO2004009085A2 (en) * 2002-07-19 2004-01-29 Ranbaxy Laboratories Limited Taste masked sumatriptan tablets and processes for their preparation
US8637512B2 (en) 2002-07-29 2014-01-28 Glaxo Group Limited Formulations and method of treatment
MXPA05005038A (en) * 2002-11-12 2005-07-01 Teva Pharma Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or bucally.
US7713455B2 (en) * 2003-11-14 2010-05-11 Sanwa Kagaku Kenkyusho Co., Ltd. Method of manufacturing a molding with a core
GB0400452D0 (en) * 2004-01-09 2004-02-11 Norton Healthcare Ltd A pharmaceutical composition
GB0403628D0 (en) * 2004-02-18 2004-03-24 Arrow Group Ltd Compression-coated tablets and the manufacture thereof
CN1921866A (en) * 2004-02-19 2007-02-28 特瓦制药工业有限公司 Therapy using a combination of raloxifene and alendronate
KR100701409B1 (en) 2004-11-26 2007-03-30 한국유나이티드제약 주식회사 Pharmaceutical formulations containing sumatriptan succinate
JP2012500221A (en) 2008-08-15 2012-01-05 ディポメド，インコーポレイティド Gastric retentive pharmaceutical composition for treatment and prevention of CNS disorders
CN110368371A (en) * 2014-04-08 2019-10-25 越洋医药开发(广州)有限公司 A kind of novel controlled release piece
JP6878417B2 (en) * 2016-02-17 2021-05-26 トリアステック インコーポレイテッド Dosage forms and their use
CN110604724A (en) * 2019-10-22 2019-12-24 恒诚制药集团淮南有限公司 Enteric mesalazine sustained-release tablet and preparation method thereof
WO2024081456A1 (en) * 2022-10-13 2024-04-18 Clarke Mosquito Control Products, Inc. Insecticidal tablet compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB972128A (en) * 1960-01-21 1964-10-07 Wellcome Found Pellets for supplying biologically active substances to ruminants and the manufacture of such pellets
JPS61243016A (en) * 1985-04-19 1986-10-29 Katsumi Takada Tablet having columnar part containing active constituent
GB8514666D0 (en) * 1985-06-11 1985-07-10 Coopers Animal Health Agent delivery systems
JPS6253918A (en) * 1985-09-02 1987-03-09 Katsumi Takada Tablet containing embedded columnar part containing active component
DE4431653C2 (en) * 1994-09-06 2000-01-20 Lohmann Therapie Syst Lts Coated tablet for the controlled release of active substances, a process for their preparation and their use
US5582838A (en) * 1994-12-22 1996-12-10 Merck & Co., Inc. Controlled release drug suspension delivery device
JP3962108B2 (en) * 1995-04-03 2007-08-22 中外製薬株式会社 Sucralfate-containing pharmaceutical composition
CA2184316A1 (en) * 1995-09-12 1997-03-13 Wei-Chi Liao Buccal delivery system for therapeutic agents
EP0931543B1 (en) * 1997-12-19 2002-03-20 MERCK PATENT GmbH Multilayered tablet comprising probiotic microorganisms such as lactobacilli or bifidobacteria
IL136460A0 (en) * 1997-12-22 2001-06-14 Schering Corp Molecular dispersion composition with enhanced bioavailability
JP4748839B2 (en) * 1999-03-25 2011-08-17 大塚製薬株式会社 Cilostazol preparation
US6499984B1 (en) * 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
JP2004513877A (en) * 2000-06-28 2004-05-13 アンジオジェニックス，アイエヌシー． Controlled release arginine preparation
EP1465606A4 (en) * 2001-12-24 2009-04-22 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it

Also Published As

Publication number Publication date
WO2003075893A1 (en) 2003-09-18
EP1492508A4 (en) 2009-05-06
JP2005524670A (en) 2005-08-18
IL163887A0 (en) 2005-12-18
EP1492508A1 (en) 2005-01-05
AU2003217909C1 (en) 2009-06-11
KR20100049695A (en) 2010-05-12
AU2003217909B2 (en) 2008-10-30
CN1649569A (en) 2005-08-03
EA005866B1 (en) 2005-06-30
NZ535083A (en) 2007-06-29
AU2003217909A1 (en) 2003-09-22
CN1649569B (en) 2010-05-05
MXPA04008536A (en) 2005-09-08
NO20044188L (en) 2004-12-03
BR0308305A (en) 2004-12-28
CA2477701A1 (en) 2003-09-18
AU2009200353A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
Nagar et al. Orally disintegrating tablets: formulation, preparation techniques and evaluation
EA200400862A1 (en) HARDWARE
SE9804314D0 (en) New pharmaceutical formulation
EA200401097A1 (en) MEDICAL FORM WITH ADJUSTABLE LIBERATION OF THE ACTIVE INGREDIENT
EA200700158A1 (en) MEDICAL FORMS WITH A TABLET NUCLEUS, COVERED WITH THE ENTEROROLEUBLISHING SHELL
MXPA03006476A (en) Pharmaceutical dosage forms of epothilones for oral administration.
DK1083879T3 (en) Devices for providing extended drug therapy
EA200801926A1 (en) TABLETS OF PARACETAMOL WITH FAST DELIVERY
HK1050493A1 (en) Shell-and-core dosage form approaching zero-order drug release
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
NO20060445L (en) Solid pharmaceutical composition comprising amisulpride
HUP0301390A2 (en) Oral pharmaceutical composition containing valsartan
BR9807992A (en) Pills to swallow which comprise paracetamol
ATE298324T1 (en) DEUTERATED 3-PIPERIDINOPROPIOPHENONE AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
JP2011173932A (en) Preparation with accurate dose-dividing function
AP2003002763A0 (en) Controlled release formulations for oral administration
ATE401075T1 (en) MEDICINAL PRODUCT CONTAINING CYTISINE
HUP0400127A2 (en) Swallow tablet comprising paracetamol
HUP0402178A2 (en) Pharmaceutical composition comprising a 5 hti receptor agonist
DE602004016963D1 (en) Therapeutisches system mit amoxicillin und clavulansäure
JP2007224021A (en) Fast-disintegrating tablet containing iguratimod
WO2002067894A3 (en) Fast dissolving tablets of cyclooxygenase-2 enzyme inhibitors
MY141008A (en) Oral formulations of deoxypeganine and their uses
JP2006206465A (en) Sustainable solid pharmaceutical preparation dissolving in oral cavity
Sarashetti et al. INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY MD RU